Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Recurrent Cervical Cancer
NCT04341883Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2020
- Primary completion
- May 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in Cervical Cancer (CC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate up to 2 years. Started Jan 2020; status: completed.
02
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04341883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04341883.